Novo Nordisk’s stock climbed 3.21 percent to €38.90 on Friday, a day when the Danish drugmaker stared down a $25 million ransomware demand from the hacking group FulcrumSec and simultaneously rattled off three operational wins. Investors overwhelmingly chose to price the pipeline over the data breach, sending the shares — still deep in the red for the year — to their best level in weeks.
The most powerful catalyst came out of Tokyo. Japan’s health regulator cleared Wegovy on June 20 for MASH, a serious fatty liver disease, based on the Phase 3 ESSENCE trial. In that study, 36.8 percent of patients on the 2.4-mg dose saw an improvement in liver fibrosis without a worsening of MASH, against just 22.4 percent in the placebo arm. The approval opens a second major therapeutic indication for Wegovy in a large market, broadening its revenue base beyond weight loss alone.
Yet it was the oral version of Wegovy that has been generating the loudest buzz on the commercial side. Since its US launch in January, the pill has racked up more than three million prescriptions, with the bulk written in the first quarter. Crucially, around 80 percent of those patients are new to GLP-1 therapy, meaning the oral formulation is expanding the addressable market rather than cannibalising the injectable franchise. That rapid uptake caught many observers off guard and helped underpin Nordea’s decision the previous day to lift its rating from Hold to Buy, setting a price target of DKK 350. The bank cited a positive news flow and the pill’s momentum, as well as a higher-dose injectable variant — dubbed Wegovy HD — that the FDA approved in March. With that 7.2-mg strength, patients lost an average of 20.7 percent of their body weight over 72 weeks; US marketing is slated to begin in April 2026.
The third piece of the day’s puzzle came from Novo Nordisk’s controlling shareholder, the Novo Nordisk Foundation. It unveiled the “CardioMetabolic Bridge” programme, a six-year, €60 million pan-European research and incubator initiative designed to translate academic work on obesity, Type 2 diabetes and heart disease into marketable products. The first laboratory is due to open in London in June 2026, with additional sites in Italy and Germany to follow. The move signals that the foundation remains committed to the therapy area despite a rough stretch for the stock.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
All that good news overshadowed the data breach, in which FulcrumSec leaked internal drug dossiers and clinical trial records after management refused to pay the $25 million ransom. While the leak carries long-term legal and intellectual property risks — misuse of specific formulas or patient data could trigger sudden volatility — the market judged neither cash flow nor the roughly 4 percent dividend yield to be immediately threatened.
Even with Friday’s bounce, Novo Nordisk shares remain about 13 percent lower year to date and more than 40 percent below the 52-week peak of €65.20. The stock has recovered nearly 29 percent from its March low of €30.25 and now trades comfortably above the 50-day moving average of €36.99. The company itself guided for a four-to-twelve percent decline in adjusted revenue for full-year 2026, a slight improvement on its earlier forecast, but US pricing pressure persists as a central worry.
Looking further out, a “patent cliff” looms around 2031, with Deutsche Bank flagging roughly $30 billion in sales at risk. In China, the semaglutide patent expired this spring, opening the door to generic copies, and Novo Nordisk needs to secure an oral Wegovy approval there quickly to defend its 65 percent market share in new obesity medicines. For now, though, the pipeline’s momentum and the resilience shown in shrugging off a ransomware attack have given bulls a fresh narrative to cling to.
Ad
Novo Nordisk Stock: Buy or Sell?! New Novo Nordisk Analysis from June 20 delivers the answer:
The latest Novo Nordisk figures speak for themselves: Urgent action needed for Novo Nordisk investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from June 20.
Novo Nordisk: Buy or sell? Read more here...
